Related Experiment Video

Updated: Jun 3, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Viral hepatitis: Treating hepatitis C in children: an open horizon

Maria Guido1, Flavia Bortolotti

  • 1Department of Medical Sciences and Special Therapies, Pathology Unit, University of Padova, Via Gabelli 61, Padua, Italy. mguido@unipd.it

Nature Reviews. Gastroenterology & Hepatology
|April 7, 2011
PubMed

Insights

Most children with chronic hepatitis C experience mild liver disease, but persistent virus replication poses risks for cirrhosis and cancer. The first controlled trial of PEG-IFN-α2a plus ribavirin offers a potential treatment approach for pediatric patients.

Area of Science:

  • Hepatology
  • Pediatric Gastroenterology
  • Virology

Background:

  • Chronic hepatitis C in children often presents with minimal liver disease but carries a long-term risk of progression.
  • Persistent hepatitis C virus (HCV) replication is a key factor in the potential development of cirrhosis and hepatocellular carcinoma.
  • Limited treatment options exist for children with chronic hepatitis C, necessitating research into effective therapies.

Discussion:

  • The study presents findings from the first controlled trial evaluating PEG-IFN-α2a plus ribavirin in children with chronic hepatitis C.
  • This combination therapy is a significant step towards establishing an appropriate treatment regimen for pediatric HCV patients.
  • The trial addresses the need for evidence-based treatments to mitigate long-term liver damage in this population.

Key Insights:

  • The controlled trial demonstrates the feasibility and potential efficacy of PEG-IFN-α2a plus ribavirin in children.
  • Early intervention with this treatment may help prevent disease progression, including cirrhosis and hepatocellular carcinoma.
  • Results support the development of targeted pediatric treatment protocols for chronic hepatitis C.

Outlook:

  • Further research and clinical trials are needed to optimize dosing and assess long-term outcomes.
  • This treatment approach could significantly alter the natural history of chronic hepatitis C in children.
  • Establishing effective pediatric treatments is crucial for reducing the global burden of liver disease and cancer.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...